Kirsch Monika, Mitchell Sandra A, Dobbels Fabienne, Stussi Georg, Basch Ethan, Halter Jorg P, De Geest Sabina
Institute of Nursing Science, University of Basel, Switzerland; Department of Haematology, University Hospital Basel, Switzerland.
Outcomes Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, United States.
Eur J Oncol Nurs. 2015 Feb;19(1):66-74. doi: 10.1016/j.ejon.2014.07.007. Epub 2014 Sep 1.
The aim of this sequential mixed methods study was to develop a PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events)-based measure of the symptom experience of late effects in German speaking long-term survivors of allogeneic stem cell transplantation (SCT), and to examine its content validity.
The US National Cancer Institute's PRO-CTAE item library was translated into German and linguistically validated. PRO-CTCAE symptoms prevalent in ≥50% of survivors (n = 15) and recognized in its importance by SCT experts (n = 9) were identified. Additional concepts relevant to the symptom experience and its consequences were elicited. Content validity of the PROVIVO (Patient-Reported Outcomes of long-term survivors after allogeneic SCT) instrument was assessed through an additional round of cognitive debriefing in 15 patients, and item and scale content validity indices by 9 experts.
PROVIVO is comprised of a total of 49 items capturing the experience of physical, emotional and cognitive symptoms. To improve the instrument's utility for clinical decision-making, questions soliciting limitations in activities of daily living, frequent infections, and overall well-being were added. Cognitive debriefings demonstrated that items were well understood and relevant to the SCT survivor experience. Scale Content Validity Index (CVI) (0.94) and item CVI (median = 1; range 0.75-1) were very high.
Qualitative and quantitative data provide preliminary evidence supporting the content validity of PROVIVO and identify a PRO-CTCAE item bundle for use in SCT survivors. A study to evaluate the measurement properties of PROVIVO and to examine its capacity to improve survivorship care planning is underway.
这项序贯混合方法研究的目的是开发一种基于PRO-CTCAE(不良事件通用术语标准的患者报告结局)的测量方法,用于评估德语区异基因造血干细胞移植(SCT)长期存活者的迟发效应症状体验,并检验其内容效度。
将美国国立癌症研究所的PRO-CTAE项目库翻译成德语并进行语言验证。确定了在≥50%的存活者(n = 15)中普遍存在且被SCT专家(n = 9)认为重要的PRO-CTCAE症状。引出了与症状体验及其后果相关的其他概念。通过对15名患者进行新一轮的认知反馈,以及9名专家对项目和量表内容效度指数的评估,来评估PROVIVO(异基因SCT后长期存活者的患者报告结局)工具的内容效度。
PROVIVO总共包含49个项目,涵盖身体、情感和认知症状的体验。为提高该工具在临床决策中的实用性,增加了询问日常生活活动受限、频繁感染和总体健康状况的问题。认知反馈表明,这些项目易于理解且与SCT存活者的经历相关。量表内容效度指数(CVI)(0.94)和项目CVI(中位数 = 1;范围0.75 - 1)非常高。
定性和定量数据提供了初步证据,支持PROVIVO的内容效度,并确定了用于SCT存活者的PRO-CTCAE项目集。一项评估PROVIVO测量特性并检验其改善生存护理计划能力的研究正在进行中。